Gilead files for fil­go­tinib in Japan; Alzheimer's flop forces some painful next steps at Neu­rotrope

→ Gilead has been right on the heels of its ri­val Ab­b­Vie with its JAK-in­hibitor fil­go­tinib. The com­pa­ny has now sub­mit­ted an NDA for the drug to the Japan­ese Min­istry of Health, La­bor and Wel­fare for the treat­ment of adults with rheuma­toid arthri­tis (RA). The sub­mis­sion is backed by da­ta from the phase III FINCH tri­al, where “once-dai­ly treat­ment with fil­go­tinib demon­strat­ed the po­ten­tial to im­prove clin­i­cal signs and symp­toms, to achieve low dis­ease ac­tiv­i­ty and re­mis­sion and to in­hib­it struc­tur­al dam­age for pa­tients liv­ing with RA.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER